Letter to the Editor of JAMA Neurology Regarding Lack of Clarity Regarding the Disclosure of Financial Conflicts of Interest

View as PDF

In a letter to the editor of JAMA Neurology, Public Citizen expressed concern about the apparent lack of clarity regarding the financial conflicts of interest disclosed by one of the authors of the Viewpoint article titled “Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease,” that was published in the February 2021 issue of JAMA Neurology. The article discussed the investigational drug aducanumab for treatment of Alzheimer’s disease.

March 1, 2021, response from the JAMA Neurology editor.

See Public Citizen’s other work on aducanumab.